Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2011

01.11.2011 | Preclinical study

Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study

verfasst von: D. G. Powe, M. J. Voss, H. O. Habashy, K. S. Zänker, A. R. Green, I. O. Ellis, F. Entschladen

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer mortality is frequently associated with metastatic disease. Metastasis models have shown adrenoceptor (AR) stimulation induces cell migration which is inhibited by adrenoceptor antagonist drugs. We investigated adrenoceptor protein expression in clinical breast tumours and its association with disease progression and prognosis. Immunohistochemistry on tissue microarrays was used to characterise α1b, α2c and β22 adrenoceptor protein expression in operable breast tumours. Associations with tumour-relevant biological markers and clinical outcome were statistically assessed. Strong α1b expression occurred in large high grade (P < 0.0001), HER2+ (P < 0.0001) or basal-like (CK5/6, P = 0.0005; CK14, P = 0.0001; EGFR, P = 0.003) cancers, showing increased proliferation (Mib1, P = 0.002), decreased apoptosis (Bcl2, P < 0.0001) and poor NPI membership (P = 0.001). α1b expression correlated with poor cancer-specific survival (LR = 7.628, P = 0.022) and tumour recurrence (LR = 6.128, P = 0.047). Strong α2c was over-expressed in high grade (P = 0.007), HER3+ (P = 0.002) and HER4+ (P < 0.0001) cancers with borderline increase in EGFR, p53 and MIB1 proteins, and inverse association with hormonal (PgR, P = 0.002) phenotype. In contrast, strong β2 expression occurred in small-size, luminal-like (ER+, P < 0.001) tumours of low grade (P < 0.001) and lymph node stage (P = 0.027) that showed poor prognosis when hormonal treatment was withheld. Adrenoceptors were not found to be independent predictors of clinical outcome. Alpha1b and α2c AR is over-expressed in basal-like breast tumours of poor prognosis. Strong β2 adrenoceptor expression is seen in patients with a luminal (ER+) tumour phenotype and good prognosis, due to benefits derived from hormonal therapy. These findings suggest a possible role for targeted therapy using adrenoceptor antagonists.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Aksien LA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Aksien LA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef
3.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRef Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRef
4.
Zurück zum Zitat Johnston SRD (2009) Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9:S28–S36PubMedCrossRef Johnston SRD (2009) Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9:S28–S36PubMedCrossRef
5.
Zurück zum Zitat Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, Richter R, Sauer H, Senn HJ, Holzel D (2003) The process of metastasisation for breast cancer. Eur J Cancer 39(12):1794–1806PubMedCrossRef Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, Richter R, Sauer H, Senn HJ, Holzel D (2003) The process of metastasisation for breast cancer. Eur J Cancer 39(12):1794–1806PubMedCrossRef
6.
Zurück zum Zitat Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS (2004) Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 5(4):254–258PubMedCrossRef Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS (2004) Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 5(4):254–258PubMedCrossRef
7.
Zurück zum Zitat Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS (2005) Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 11(3):403–411PubMedCrossRef Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS (2005) Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 11(3):403–411PubMedCrossRef
8.
Zurück zum Zitat Masur K, Niggemann B, Zaenker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61(7):2866–2869PubMed Masur K, Niggemann B, Zaenker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61(7):2866–2869PubMed
9.
Zurück zum Zitat Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112(2):231–238PubMedCrossRef Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112(2):231–238PubMedCrossRef
10.
Zurück zum Zitat Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63–70PubMedCrossRef Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63–70PubMedCrossRef
11.
Zurück zum Zitat Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS, Entschladen F (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118(11):2744–2749PubMedCrossRef Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS, Entschladen F (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118(11):2744–2749PubMedCrossRef
12.
Zurück zum Zitat Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12(2):369–375PubMedCrossRef Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12(2):369–375PubMedCrossRef
13.
Zurück zum Zitat Dorn GW, Liggett SB (2008) Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure. CTS Clin Transl Sci 1(3):255–262CrossRef Dorn GW, Liggett SB (2008) Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure. CTS Clin Transl Sci 1(3):255–262CrossRef
14.
Zurück zum Zitat Rosini M, Bolognesi ML, Giardina D, Minarini A, Tumiatti V, Melchiorre C (2007) Recent advances in alpha(1)-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. Curr Top Med Chem 7(2):147–162PubMedCrossRef Rosini M, Bolognesi ML, Giardina D, Minarini A, Tumiatti V, Melchiorre C (2007) Recent advances in alpha(1)-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. Curr Top Med Chem 7(2):147–162PubMedCrossRef
15.
Zurück zum Zitat Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT et al (2007) Effect of alpha 1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178(5):2176–2180PubMedCrossRef Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT et al (2007) Effect of alpha 1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178(5):2176–2180PubMedCrossRef
16.
Zurück zum Zitat Algazi M, Plu-Bureau G, Flahault A, Dondon MG, Le MG (2006) Is beta-blocker treatment associated with a decrease in the risk of cancer. Lett Drug Des Discov 3(9):653–661CrossRef Algazi M, Plu-Bureau G, Flahault A, Dondon MG, Le MG (2006) Is beta-blocker treatment associated with a decrease in the risk of cancer. Lett Drug Des Discov 3(9):653–661CrossRef
17.
Zurück zum Zitat Abdel-Fatah TMA, Powe DG, Ball G, Reis JS, Ellis IO (2009) The need for a biological grading system and its relationship to the current Nottingham histological grading system (NGS). EJC Suppl 7(2):264–265 Abdel-Fatah TMA, Powe DG, Ball G, Reis JS, Ellis IO (2009) The need for a biological grading system and its relationship to the current Nottingham histological grading system (NGS). EJC Suppl 7(2):264–265
18.
Zurück zum Zitat El-Rehim D, Ball G, Pinder S, Rakha E, Paish C, Robertson J, Macmillan D, Blamey R, Ellis I (2005) High throughput protein expression analysis using tissue microarray technology of a large well -characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350CrossRef El-Rehim D, Ball G, Pinder S, Rakha E, Paish C, Robertson J, Macmillan D, Blamey R, Ellis I (2005) High throughput protein expression analysis using tissue microarray technology of a large well -characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350CrossRef
19.
Zurück zum Zitat El-Rehim DMA, Ball G, Pinder S, Ellis IO (2004) Molecular classification of breast carcinoma based on the protein expression immunoprofiles. J Pathol 204:3A–4A El-Rehim DMA, Ball G, Pinder S, Ellis IO (2004) Molecular classification of breast carcinoma based on the protein expression immunoprofiles. J Pathol 204:3A–4A
20.
Zurück zum Zitat Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44(11):1541–1551PubMedCrossRef Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44(11):1541–1551PubMedCrossRef
21.
Zurück zum Zitat McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235PubMedCrossRef McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235PubMedCrossRef
22.
Zurück zum Zitat Luthy IA, Bruzzone A, Pinero CP, Castillo LF, Chiesa IJ, Vazquez SM, Sarappa MG (2009) Adrenoceptors: non-conventional target for breast cancer? Curr Med Chem 16(15):1850–1862PubMedCrossRef Luthy IA, Bruzzone A, Pinero CP, Castillo LF, Chiesa IJ, Vazquez SM, Sarappa MG (2009) Adrenoceptors: non-conventional target for breast cancer? Curr Med Chem 16(15):1850–1862PubMedCrossRef
23.
Zurück zum Zitat Badino G, Novelli A, Girardi C, Carlo FD (1996) Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res 33(4–5):255–260PubMed Badino G, Novelli A, Girardi C, Carlo FD (1996) Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res 33(4–5):255–260PubMed
24.
Zurück zum Zitat Marchetti B, Fortier MA, Poyet P, Follea N, Pelletier G, Labrie F (1990) Beta-adrenergic receptors in the rat mammary gland during pregnancy and lactation—characterization, distribution, and coupling to adenylate cyclase. Endocrinology 126(1):565–574PubMedCrossRef Marchetti B, Fortier MA, Poyet P, Follea N, Pelletier G, Labrie F (1990) Beta-adrenergic receptors in the rat mammary gland during pregnancy and lactation—characterization, distribution, and coupling to adenylate cyclase. Endocrinology 126(1):565–574PubMedCrossRef
25.
Zurück zum Zitat Slotkin TA, Zhang JA, Dancel R, Garcia SJ, Willis C, Seidler FJ (2000) Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 60(2):153–166PubMedCrossRef Slotkin TA, Zhang JA, Dancel R, Garcia SJ, Willis C, Seidler FJ (2000) Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 60(2):153–166PubMedCrossRef
26.
Zurück zum Zitat Vandewalle B, Revillion F, Lefebvre J (1990) Functional adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116(3):303–306PubMedCrossRef Vandewalle B, Revillion F, Lefebvre J (1990) Functional adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116(3):303–306PubMedCrossRef
27.
Zurück zum Zitat Shang ZJ, Liu K, Liang DF (2009) Expression of beta(2)-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 38(4):371–376PubMedCrossRef Shang ZJ, Liu K, Liang DF (2009) Expression of beta(2)-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 38(4):371–376PubMedCrossRef
28.
Zurück zum Zitat Draoui A, Vandewalle B, Hornez L, Revillion F, Lefebvre J (1991) Beta-adrenergic receptors in human breast cancer—characterization and correlation with progesterone and estradiol receptors. Anticancer Res 11(2):677–680PubMed Draoui A, Vandewalle B, Hornez L, Revillion F, Lefebvre J (1991) Beta-adrenergic receptors in human breast cancer—characterization and correlation with progesterone and estradiol receptors. Anticancer Res 11(2):677–680PubMed
29.
Zurück zum Zitat Schuller HM (2007) Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. Neuronal Act Tumor Tissue 39:45–63CrossRef Schuller HM (2007) Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. Neuronal Act Tumor Tissue 39:45–63CrossRef
30.
Zurück zum Zitat Lancashire L, Powe D, Reis-Filoh J, Rakha E, Lemetre C, Weigelt B, Abdel-Fatah T, Green A, Mukta R, Blamey R et al (2010) A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res Treat 120(1):83–93PubMedCrossRef Lancashire L, Powe D, Reis-Filoh J, Rakha E, Lemetre C, Weigelt B, Abdel-Fatah T, Green A, Mukta R, Blamey R et al (2010) A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res Treat 120(1):83–93PubMedCrossRef
31.
Zurück zum Zitat Al-Wadei HA, Al-Wadei MH, Schuller HM (2009) Prevention of pancreatic cancer by the beta-blocker propranolol. Anti-Cancer Drugs 20(6):477–482PubMedCrossRef Al-Wadei HA, Al-Wadei MH, Schuller HM (2009) Prevention of pancreatic cancer by the beta-blocker propranolol. Anti-Cancer Drugs 20(6):477–482PubMedCrossRef
32.
Zurück zum Zitat Powe DG, Habashy HO, Voss MH, Zaenker KS, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628–638 Powe DG, Habashy HO, Voss MH, Zaenker KS, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628–638
33.
Zurück zum Zitat Hui HX, Fernando MA, Heaney AP (2008) The alpha(1)-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappa B signalling to induce breast cancer cell apoptosis. Eur J Cancer 44(1):160–166PubMedCrossRef Hui HX, Fernando MA, Heaney AP (2008) The alpha(1)-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappa B signalling to induce breast cancer cell apoptosis. Eur J Cancer 44(1):160–166PubMedCrossRef
34.
Zurück zum Zitat Lowe FC (2004) Role of the newer alpha(1)-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26(11):1701–1713PubMedCrossRef Lowe FC (2004) Role of the newer alpha(1)-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26(11):1701–1713PubMedCrossRef
35.
Zurück zum Zitat Chiu G, Connolly PJ, Middleton SA, Li SJ, Pulito V, Liu JC, Baxter EW, Reitz AB (2008) Alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. Expert Opin Therap Pat 18(12):1351–1360CrossRef Chiu G, Connolly PJ, Middleton SA, Li SJ, Pulito V, Liu JC, Baxter EW, Reitz AB (2008) Alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. Expert Opin Therap Pat 18(12):1351–1360CrossRef
Metadaten
Titel
Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study
verfasst von
D. G. Powe
M. J. Voss
H. O. Habashy
K. S. Zänker
A. R. Green
I. O. Ellis
F. Entschladen
Publikationsdatum
01.11.2011
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1371-z

Weitere Artikel der Ausgabe 2/2011

Breast Cancer Research and Treatment 2/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.